{"id":548185,"date":"2021-06-17T17:30:01","date_gmt":"2021-06-17T17:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=548185"},"modified":"2021-06-17T17:30:01","modified_gmt":"2021-06-17T17:30:01","slug":"chronic-hepatitis-delta-virus-infection-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-janssen-pharmaceuticals-eiger-biopharmaceutical-pharma-essentia-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-hepatitis-delta-virus-infection-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-janssen-pharmaceuticals-eiger-biopharmaceutical-pharma-essentia-and-many-others_548185.html","title":{"rendered":"Chronic Hepatitis Delta Virus Infection Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Janssen Pharmaceuticals, Eiger Biopharmaceutical, Pharma Essentia and Many Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1623898958.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Hepatitis Delta Virus Infection Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Janssen Pharmaceuticals, Eiger Biopharmaceutical, Pharma Essentia and Many Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1623898958.jpeg\" alt=\"Chronic Hepatitis Delta Virus Infection Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Janssen Pharmaceuticals, Eiger Biopharmaceutical, Pharma Essentia and Many Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Chronic Hepatitis Delta Virus Infection Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Chronic Hepatitis Delta Virus Infection<\/a><\/strong> is caused by hepatitis D virus with simultaneous presence of hepatitis B infection. HDV-HBV co-infection is the most severe form of chronic infection leading liver-related death and hepatocellular carcinomas. The virus can transmit from person to person and affect nearly 5% of population with prior HBV infection.&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Chronic Hepatitis Delta Virus Infection Pipeline Insight, 2021<\/strong>,&rdquo; report provides comprehensive insights about <strong>5+ companies and 5+ pipeline drugs<\/strong> in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Hepatitis Delta Virus Infection Key Players:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Janssen Pharmaceuticals<\/li>\n<li>Eiger Biopharmaceutical<\/li>\n<li>Pharma Essentia<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Chronic Hepatitis Delta Virus Infection report covers around 5+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II and Phase I\/II)<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Chronic Hepatitis Delta Virus Infection Therapies<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>JNJ-73763989<\/li>\n<li>Lonafarinib<\/li>\n<li>P1101<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Chronic Hepatitis Delta Virus Infection Treatment Scenario and Chronic Hepatitis Delta Virus Infection Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Chronic Hepatitis Delta Virus (HDV) Infection drugs?<\/li>\n<li>How many Chronic Hepatitis Delta Virus (HDV) Infection drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Hepatitis Delta Virus (HDV) Infection?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Chronic Hepatitis Delta Virus (HDV) Infection therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Chronic Hepatitis Delta Virus (HDV) Infection and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Chronic Hepatitis Delta Virus (HDV) Infection: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Chronic Hepatitis Delta Virus (HDV) Infection &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Chronic Hepatitis Delta Virus (HDV) Infection Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Lonafarnib: Eiger Biopharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">JNJ-73763989: Janssen Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Pre-clinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Chronic Hepatitis Delta Virus (HDV) Infection Key Companies<\/p>\n<p style=\"text-align: justify;\">Chronic Hepatitis Delta Virus (HDV) Infection Key Products<\/p>\n<p style=\"text-align: justify;\">Chronic Hepatitis Delta Virus (HDV) Infection- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Chronic Hepatitis Delta Virus (HDV) Infection- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Chronic Hepatitis Delta Virus (HDV) Infection- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Chronic Hepatitis Delta Virus (HDV) Infection Analyst Views<\/p>\n<p style=\"text-align: justify;\">Chronic Hepatitis Delta Virus (HDV) Infection Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-hepatitis-delta-virus-infection-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-janssen-pharmaceuticals-eiger-biopharmaceutical-pharma-essentia-and-many-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/chronic-hepatitis-delta-virus-hdv-infection-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-hepatitis-delta-virus-infection-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-janssen-pharmaceuticals-eiger-biopharmaceutical-pharma-essentia-and-many-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chronic Hepatitis Delta Virus Infection Pipeline Chronic Hepatitis Delta Virus Infection is caused by hepatitis D virus with simultaneous presence of hepatitis B infection. HDV-HBV co-infection is the most severe form of chronic infection leading liver-related death and hepatocellular carcinomas. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-hepatitis-delta-virus-infection-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-janssen-pharmaceuticals-eiger-biopharmaceutical-pharma-essentia-and-many-others_548185.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-548185","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/548185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=548185"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/548185\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=548185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=548185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=548185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}